Compare OFS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFS | SCLX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | 47 | 34 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 55.1M |
| IPO Year | N/A | N/A |
| Metric | OFS | SCLX |
|---|---|---|
| Price | $3.36 | $6.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.0K | ★ 119.0K |
| Earning Date | 04-30-2026 | 04-10-2026 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $4.20 |
| 52 Week High | $8.99 | $34.27 |
| Indicator | OFS | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 39.46 |
| Support Level | $3.29 | $5.72 |
| Resistance Level | $4.01 | $7.77 |
| Average True Range (ATR) | 0.13 | 0.79 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 40.00 | 0.27 |
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.